RNA N1-Methyladenosine (m1A) Analysis

N1-methyladenosine (m1A) is a pivotal and reversible RNA modification that introduces a positive charge to regulate RNA structure and function with significant implications for gene expression. CD BioSciences provides expert, end-to-end m1A analysis services, employing robust methods to accurately map and quantify this dynamic modification across diverse RNA species.

Introduction to N1-Methyladenosine (m1A)

N1-methyladenosine (m1A) is a conserved post-transcriptional modification where a methyl group is added to the N1 position of adenosine, conferring a positive charge and sterically hindering Watson-Crick base pairing. This unique chemical property underlies its distinct biological roles. m1A is predominantly found in transfer RNA (tRNA) and ribosomal RNA (rRNA), where it is crucial for stabilizing tertiary structure and ensuring translational fidelity. Its discovery in messenger RNA (mRNA) and long non-coding RNA has revealed an additional layer of gene regulation, where it can influence RNA stability, splicing, and most notably, inhibit translation elongation by disrupting ribosome progression—a function that contrasts with many other modification types. Dysregulation of m1A is strongly linked to human diseases, particularly various cancers and mitochondrial disorders, making its precise analysis essential for uncovering novel disease mechanisms and therapeutic targets in the rapidly evolving field of epitranscriptomics.

Fig.1 Some of the known readers (green), writers (blue), and erasers (ochre) of the m1A modification of the tRNA molecule. (Kvolik Pavić A, et al., 2024)

Our Services

CD BioSciences offers specialized solutions to overcome the historical technical challenges in m1A detection. We provide a complete suite of validated techniques designed for the sensitive and specific identification of m1A sites, delivering reliable data that enables researchers to decipher the functional impact of this critical modification in their biological systems.

Customized m1A Analysis Solution

At CD BioSciences, we provide a fully customized m1A analysis solution designed to address the specific challenges and goals of your research. Our expert team works with you to select the optimal technology mix based on your sample type, biological question, and desired depth of analysis, ensuring you obtain definitive and actionable insights into the role of m1A in your system.

Workflow of RNA m1A Analysis Service

Supported Sample Types

1. Cultured Cell Lines
2. Animal/Plant Tissues
3. Whole Blood or PBMCs
4. Cell-free Plasma/Serum

1. FFPE Samples
2. Specific RNA Fractions
3. In Vitro Transcribed (IVT) RNA
4. Other Types (Please Inquire)

Our Advantages

1. Guarantee High Specificity: Overcome detection challenges by employing validated antibody-based enrichment and orthogonal chemical methods to minimize false positives and ensure accurate m1A identification.
2. Provide End-to-End Expertise: Leverage deep knowledge in m1A biochemistry to guide project design, troubleshoot technical hurdles, and deliver biologically meaningful data interpretation.
3. Enable Functional Insights: Integrate m1A mapping data with ribosome profiling or RNA-seq to directly correlate modification sites with translational outcomes and gene expression changes.
4. Support Diverse Research Goals: Deliver tailored solutions suitable for both discovery-phase mapping and rigorous validation studies, applicable to fundamental research and translational biomarker discovery.

In addition to m1A analysis, CD BioSciences also provides expert services for m6A, m5C, ac4C, Ψ, m6Am, m7G and RNA adenosine-to-inosine (A-to-I) editing analysis. We are committed to delivering comprehensive and customized epitranscriptomic solutions to provide robust data support for your research in gene regulation, disease mechanism exploration, and biomarker discovery. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

Reference

1. Kvolik Pavić A, Čonkaš J, Mumlek I, et al. Clinician's Guide to Epitranscriptomics: An Example of N1-Methyladenosine (m1A) RNA Modification and Cancer[J]. Life, 2024, 14(10): 1230.